Approved at Faculty Meeting January 22, 2008
Modified November 22, 2008
Approved January 20, 2009
Updated April 9, 2019
Approved April 30, 2019

POLICY FOR CLINICAL FACULTY AND SUPPORT STAFF WITH INFECTIOUS DISEASES

FACULTY OF DENTISTRY
DALHOUSIE UNIVERSITY

Principles:
The Faculty of Dentistry at Dalhousie University is committed to protecting and maintaining the rights of patients and health care workers (HCWs) as well as the integrity of the educational process of dental professionals.

The provision of patient care at Faculty of Dentistry (through each of its clinical programs) is delivered primarily through students under the direct supervision of clinical faculty and with the support of clinical support staff. The clinical experiences provided include exposure-prone procedures (1-4). These exposure-prone procedures have been determined to pose an increased risk of bloodborne disease transmission due to their nature and the type of instruments and devices typically used for exposure-prone procedures (5-7). Therefore, students, clinical faculty and clinical support staff cannot avoid involvement in the provision of patient care activities that involve exposure-prone procedures. For this reason, the Faculty of Dentistry has determined that the performance of exposure-prone procedures places patients at increased risk.

Entry into the health care professions is a privilege offered to those who are prepared for a lifetime of service to the public. Students, faculty and all HCWs have a fundamental responsibility to provide care to all patients assigned to them without prejudice and to ensure that care is delivered competently and safely. A failure to accept this responsibility violates a basic tenet of the dental profession – to place the patient's interest and welfare first. For this reason, all HCWs have an ethical obligation to their patients to know their own infectious disease status (especially with respect to HBV, HCV and HIV). If negative to HBV, HCV and HIV, testing should be performed on a schedule based on the individual's level of risk and whenever an exposure occurs (7).

Health care workers are at risk of contracting infectious diseases during the course of patient care activities (8). A policy of mandatory immunizations and Routine Practices (Standard Precautions) can protect HCWs from some of these infectious diseases.

Percutaneous injuries can place a HCW at risk to occupational exposure to HBV, HCV and HIV. Therefore, training and education on the prevention of injuries is an absolute necessity for all HCWs.

In order to minimize the risk of transmission of bloodborne viruses (BBV) from HCW to patient, the HCW must adhere to Routine Practices, including proper handwashing, use of PPE as required and adherence to the proper management of sharps. When the HCW follows these guidelines, the risk of transmission of a BBV from HCW to patient is negligible. If exposure-prone procedures (EPPs) are performed, the risk of transmission is slightly higher but is still minimal. Although impossible to attain zero risk of BBV transmission from a HCW to a patient, the risk can be made negligible due to the efficacy of the HB vaccine and effective drug regimens to suppress HCV and HIV (7).

Any faculty member or clinical support staff working in any clinical program within the Faculty of Dentistry infected with a BBV will receive counselling regarding their BBV status (7).

Terms
"Clinical Programs" includes but is not limited to Dentistry, Qualifying Program, Dental Hygiene, Bachelor of Dental Hygiene, Graduate Periodontics Residents, General Practice Residents, Paediatric Dentistry Residents and OMFS Residents. This also includes any courses, short programs, re-licensure or re-entry programs within these jurisdictions.

"Exposure-prone procedures" (EPP) "Exposure-prone procedures (EPPs) are invasive procedures where there is a risk that injury to the HCW may result in the exposure of the patient's open tissues to the blood of the HCW. For transmission of a BBV from an infected HCW to patient to occur during an EPP, three conditions are necessary (9):*
1. HCW must sustain an injury or have a condition that allows for exposure
2. HCW's blood must come in contact with a patient's wound, traumatized tissue,

mucous membranes, or similar portal of entry
3. HCW must be sufficiently viremic EPPs with risk of transmission include (10):
- *a. Digital palpation of a needle tip in a body cavity (a hollow space within the body or one of its organs); or the simultaneous presence of the HCW's fingers and a needle or other sharp instrument or object (such as bone splinters, sternal wires etc.) in a blind or highly confined anatomic site, e.g., as may occur during major abdominal, cardiothoracic, vaginal, pelvic and/or orthopedic operations*
- *b. Repair of major traumatic injuries*
- *c. Cutting or removal of any oral or perioral tissue, during which the patient's open tissues may be exposed to the blood of an injured infected HCW."*

** The definition of EPP is taken directly from the 2018 Public Health Agency of Canada's"* ***Guideline on the Prevention of Transmission of Bloodborne Viruses from Infected Healthcare Workers in Healthcare Settings".*** *The guideline does not provide a list of risk categories for EPPs due to the lack of sufficient evidence to accurately categorize the transmission risk of dental and medical procedures. The PHAC guideline recommends that experts in the discipline or specialty determine which procedures fit into the category of an EPP* (7)***.***

"HBV" means hepatitis B virus.

"HCV" means hepatitis C virus.

"HIV" means human immunodeficiency virus.

"HCW" means health care worker and includes students, student applicant and resident trainees.

"Non-responders" or "individuals with inadequate antibody titres" refer to individuals susceptible to Hepatitis B due to inadequate antibody titres. Such individuals have a titre <u>≤</u> 10 mIU/mL (or IU/L) for anti-HbsAg (11).

"Students" include all students and residents in undergraduate and graduate dental and dental hygiene programs.

1.0 Immunization and Immunity status of clinical faculty and clinical support staff

All clinical faculty and clinical support staff shall maintain their own record of immunizations using the Dalhousie University, Faculty of Dentistry Immunization Record (**Appendix 1**) that provides evidence of required immunizations, post-serological testing and evidence of immunity.

2.0 Hepatitis B immunization for clinical faculty and clinical support staff

All clinical faculty and clinical support staff must be immunized against Hepatitis B unless a medical contraindication is present.

All clinical faculty and clinical support staff must demonstrate immunity to HB (anti-HBs >10 IU/L) prior to the beginning of any clinical activities.

If immunity is not acquired after the first 3-dose series, a second 3-dose series should be initiated. Post-serological testing must occur 1-6 months following completion of the 3-dose series and the results recorded on their Immunization Record.

Should the second 3-dose series fail to result in immunity, consultation with occupational health or infectious diseases specialists should be initiated. The clinical faculty and clinical support staff will need to be tested at an interval determined by their level of risk (in consultation with their physician) and whenever an exposure occurs.

Any clinical faculty or clinical support staff who were born in or previously resided in high or intermediate HBV endemic countries (**Table 1**) must be tested for anti-HBc and HBsAg in addition to anti-HBs to fully determine their HBV status (7).

3.0 Faculty or clinical support staff (Clinical Nurse) infected with HBV

Any clinical faculty or clinical support staff (Clinical Nurse) infected with HBV is restricted from performing EPPs until the HCW:

a. is under the care of a physician with expertise in the management of HBV
b. is medically managed according to current recommendations
c. has regular scheduled monitoring of their HBV DNA level
AND
d. has a HBV DNA level below 10^3 IU/ml (5 x 10^3 GE/ml) and the HBV DNA level is assessed regularly (every 3 to 6 months)

Clinical faculty or clinical support staff (Clinical Nurse) who have HBV DNA level below 10^3 IU/ml (5 x 10^3 GE/ml) would not have any practice restrictions based on their HBV status on its own.

If a HCW-to-patient transmission of HBV occurs, the HCW must cease all patient care activities immediately until a determination for fitness to return to practice is made by an expert panel (**Ad-hoc Committee on Bloodborne Pathogens -** College of Physicians and Surgeons of Nova Scotia - 421-2209). If the recommendation from the Committee is to refrain from patient care activities, then such clinical faculty or clinical support staff shall inform others as necessary depending on circumstances, but in all circumstances shall inform the Assistant Dean, Clinics and the Clinical Nurse.

Hepatitis B is a highly infectious disease. The HBV can remain infectious on environmental surfaces for up to 7 days and can be transmitted even in the absence of visible blood (12-15). Hepatitis B is 100 times more infectious than HIV and 10 times more infectious than Hepatitis C (16-18).

The key marker for determining infectivity of HB used to be the presence of HBe antigen (19, 20). However, it is now recognized that a small subset of people can be HBe negative and have a high viral load (10, 21). Therefore, the standard for measuring HB infectivity currently is a measure of viral load (22-27).

Studies have shown that there can be significant fluctuations in viral load in patients that are HBe negative and even higher fluctuations in viral load in patients not on treatment (7, 22, 28).

Any HCWs infected with HIV, HCV and/or HBV that are not performing EPPs do not need to have any restrictions on their practice based on their BBV status alone (7).

4.0 Declination of Hepatitis B vaccine or Non-Responders to the Hepatitis B vaccine

Clinical faculty or clinical support staff declining to be immunized against Hepatitis B or are non-responders are to be counseled by the Assistant Dean, Clinics and Building Services and the Clinical Nurse prior to beginning their clinical activities and their request for accommodation in the nature of a waiver of this admission requirement will be assessed on case-by-case basis (7, 29, 30).

Any clinical faculty or clinical support staff declining the hepatitis B vaccine series or are non-responders must agree to sign **The Agreement Form for Hepatitis B Antibody, Antigen and Viral DNA Testing** (**Appendix 3**) and the **Hepatitis B Vaccine Declination Statement** (if applicable) (**Appendix 4**).

Any clinical faculty or clinical support staff becoming HBsAg positive and whose viral load exceeds 10^3 IU/ml (5 x 10^3 GE/ml) during the course of their employment will be removed from patient care (31). If and when the clinical faculty or clinical support staff is under the care of a physician with expertise in the management of Hepatitis B and the viral load has been reduced to below this threshold, the clinical faculty or clinical support staff will then have no clinical restrictions.

5.0 Management of HCWs infected with HCV

Any clinical faculty or clinical support staff (Clinical Nurse) infected with HCV should be seen by a physician that has expertise in HCV management and managed and monitored according to the current recommendations.

Clinical faculty or clinical support staff (Clinical Nurse) are restricted from performing EPPs until the HCW:

a) is under the care of a physician with expertise in the management of HCV
b) has completed a course of effective antiviral therapy
AND
c) has an undetectable viral load at least 12 weeks post-treatment

If there is a transmission from HCW to patient, the HCW must cease practice immediately until it has been determined by an expert panel that he/she is fit to return to practice (7).

6.0 Management of HCWs infected with HIV

Clinical faculty or clinical support staff (Clinical Nurse) should be tested for HIV at an interval determined by their level of risk and whenever an exposure has occurred.

Clinical faculty or clinical support staff (Clinical Nurse) infected with HIV should be seen by a physician that has expertise in HIV management and managed and monitored according to the current recommendations.

Clinical faculty or clinical support staff (Clinical Nurse) are restricted from performing EPPs until the HCW:

a) is under the care of a physician with expertise in the management of HIV
b) is on effective antiretroviral therapy or has been diagnosed as an elite controller
AND
c) has an undetectable viral load

If there is a transmission from HCW to patient, the HCW must cease practice immediately until it has been determined by an expert panel that he/she is fit to return to practice (7).

7.0. Communicable Disease Status

Any clinical faculty or clinical support staff who develop an infectious disease during the course of their clinical activities disease is required to comply with the recommendations in **Table 2**..

Each situation will be assessed on a case-by-case basis.

With respect to medical conditions, work related illness and work restrictions, clinical faculty or clinical support staff in the Faculty of Dentistry are responsible for monitoring their own health status. HCWs who have acute or chronic medical conditions that render them susceptible to opportunistic infection should discuss with their personal physician(s), the Assistant Dean, Clinics and the Clinical Nurse whether the condition might affect their ability to safely perform their duties. It is the ethical obligation of the HCW to report such conditions to the Dean's office. The Assistant Dean, Clinics has the authority and responsibility to exclude clinical faculty or clinical support staff from work or patient contact to prevent further transmission of infection. Decisions concerning work restrictions will be based on the mode of transmission and the period of infectivity of the disease (see Table 2) (29, 31-34).

This policy is consistent with the Canadian Dental Association's Code of Ethics which states, under Article 2, Competency (35): *"A practitioner should inform the dental licencing authority when a serious injury, dependency, infection or other condition has either immediately affected, or may affect over time, his or her ability to practice safely and competently."*

The reporting obligations will be consistent with the requirements of the Nova Scotia Government.

Approved at Faculty Meeting January 22, 2008
Modified November 22, 2008
Approved January 20, 2009
Updated April 9, 2019
Approved April 30, 2019

Table 1. HBV Endemic Countries



MAP 3-4. PREVALENCE OF CHRONIC HEPATITIS B VIRUS INFECTION AMONG ADULTS[1]
[1] Disease data source: Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30(12): 2212-2219.

List of countries by prevalence of chronic hepatitis B virus infection among adults:

High (≥8%): Benin, Burkina Faso, Cameroon, Cape Verde, Chad, Côte d'Ivoire, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, São Tomé and Príncipe, Senegal, Sierra Leone, Togo

High Intermediate (5%-7%): Angola, Armenia, Azerbaijan, Botswana, Burundi, Cambodia, Central African Republic, China, Comoros, Congo, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Federal States of Micronesia, Fiji, Gabon, Georgia, Indonesia, Kazakhstan, Kenya, Kiribati, Kyrgyzstan, Lao People's Democratic Republic, Lesotho, Madagascar, Malawi, Malaysia, Maldives, Marshall Islands, Mauritius, Mongolia, Mozambique, Myanmar, Namibia, Papua New Guinea, People's Republic of Korea, Philippines, Rwanda, Samoa, Seychelles, Solomon Islands, Somalia, South Africa, Sri Lanka, Sudan, Swaziland, Taiwan, Tajikistan, Thailand, Tonga, Turkmenistan, Uganda, United Republic of Tanzania, Uzbekistan, Vanuatu, Zambia, Zimbabwe

Low Intermediate (2%-4%): Afghanistan, Albania, Algeria, Argentina, Aruba, Australia, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belize, Bhutan, Bolivia, Bosnia and Herzegovina, Brunei Darussalam, Bulgaria, Chile, Croatia, Cuba, Czech Republic, Dominica, Dominican Republic, Ecuador, Egypt, Estonia, Grenada, Guyana, Haiti, Hungary, India, Iraq, Islamic Republic of Iran, Jamaica, Japan, Jordan, Latvia, Lebanon, Libyan Arab Jamahiriya, Lithuania, Macedonia, Martinique, Moldova, Montenegro, Morocco, Nepal, Netherlands Antilles, New Zealand, Pakistan, Palestine, Peru, Poland, Puerto Rico, Republic of Korea, Romania, Russian Federation, Saint Lucia, Saint Vincent and the Grenadines, Singapore, Suriname, Trinidad and Tobago, Ukraine, Uruguay

Low (<1%): Andorra, Austria, Belgium, Brazil, Canada, Colombia, Costa Rica, Cyprus, Denmark, El Salvador, Finland, France, Germany, Greece, Guatemala, Honduras, Iceland, Ireland, Israel, Italy, Mexico, Nicaragua, Panama, Paraguay, United States of America, Venezuela
No data: Serbia

Source: https://www.cdc.gov/travel-static/yellowbook/2016/map_3-04.pdf

Table 2. Work Restriction Guidelines for HCWs with Infectious Diseases

Table 2	**Work restrictions for HCWs in clinical programs infected with or exposed to major infectious diseases in health care settings.**	
Disease/Problem	**Clinical Restriction**	**Duration**
Conjunctivitis	Restrict from patient contact and contact with patient's environment.	Until discharge ceases.
Cytomegalovirus Infection	No restriction	
Diarrheal Disease Acute stage (diarrhea with other symptoms) Convalescent stage Salmonella species	 Restrict from patient contact, contact with patient's environment, and food handling Restrict care of patients at high risk	 Until symptoms resolve. Until symptoms resolve; consult with local and provincial health authorities regarding need for negative stool cultures.
Enteroviral Infection	Restrict from care of infants, neonates, and immunocompromised patients and their environments	Until symptoms resolve.
Hepatitis A	Restrict from patient contact, contact with patient's environment, and food handling.	Until 7 days after onset of jaundice.

Table 2 (continued)	**Work restrictions for HCWs in clinical programs infected with or exposed to major infectious diseases in health care settings.**	
Disease/Problem	**Clinical Restriction**	**Duration**
Herpes simplex Genital	No restrictions	
Hands (herpetic whitlow)	Restrict from patient contact and contact with patient's environment.	Until lesions heal.
Orofacial	Evaluate need to restrict from care of patients at high risk.	See Faculty Guidelines on Management of Patients with Herpetic Lesions.
Human immunodeficiency virus	Do not perform exposure-prone procedures until counsel from the **Ad-hoc Committee on Bloodborne Pathogens** has been sought; Committee should review and recommend procedures that personnel can perform, taking into account specific procedures as well as skill and technique. Routine practices are always to be followed.	
Measles Active	Exclude from clinical activity	Until 7 days after the rash appears.
Post exposure (susceptible personnel)	Exclude from clinical activity	From fifth day after first exposure through twenty-first day after last exposure or 4 days after rash appears.
Meningococcal infection	Exclude from clinical activity	Until 24 hours after start of effective therapy.
Mumps Active	Exclude from clinical activity	Until 9 days after onset of parotitis.
Post exposure (susceptible personnel)	Exclude from clinical activity	From twelfth day after first exposure through twenty-sixth day after last exposure, or until 9 days after onset of parotitis.

Table 2 (continued)	**Work restrictions for HCWs in clinical programs infected with or exposed to major infectious diseases in health care settings.**	
Disease/Problem	**Clinical Restriction**	**Duration**
Pediculosis	Exclude from clinical activity	Until treated and observed to be free of adult and immature lice.
Pertussis Active	Exclude from clinical activity	From beginning of catarrhal stage through third week after onset of paroxysms or until 5 days after start of effective antibiotic therapy.
Post exposure (asymptomatic personnel)	No restriction, prophylaxis recommended	
Post exposure (symptomatic personnel)	Exclude from clinical activity	Until 5 days after start of effective antibiotic therapy.
Rubella Active	Exclude from clinical activity	Until 5 days after rash appears.
Post exposure (susceptible personnel)	Exclude from clinical activity	From 7th day after first exposure through twenty-first day after last exposure.
Staphylococcus aureus infection Active, draining skin lesion	Exclude from clinical activity	Until lesions have resolved
Carrier state	No restriction unless personnel are epidemiologically linked to transmission of the organism.	
Streptococcal Infection, group A	Exclude from clinical activity	Until 24 hours after adequate treatment is started.
Tuberculosis Active disease	Exclude from clinical activity	Until proven non-infectious
Positive TST (latent TB)	No restriction	

Table 2 (continued)	**Work restrictions for HCWs in clinical programs infected with or exposed to major infectious diseases in health care settings.**	
Disease/Problem	**Clinical Restriction**	**Duration**
Varicella (Chicken pox) Active disease	Exclude from clinical activity	Until all lesions dry and crust.
Post exposure (susceptible personnel)	Exclude from clinical activity	From tenth day after first exposure through twenty-first day (twenty-eighth day if varicella- zoster immune globulin [VZIG] administered) after last exposure.
Zoster (shingles) Localized, in healthy person	Cover lesions, restrict from care of patients at high risk	Until all lesions dry and crust.
Generalized or localized in immunosuppressed person	Exclude from clinical activity	Until all lesions dry and crust.
Post exposure (susceptible personnel)	Exclude from clinical activity	From tenth day after first exposure through twenty-first day (twenty-eighth day if varicella-zoster immune globulin [VZIG] administered) after last exposure or if varicella occurs when lesions crust and dry.
Viral respiratory infection, acute febrile	Consider excluding from care patients at high risk, or contact with such patients' environment during community outbreak of respiratory syncytial virus and influenza	Until acute symptoms resolve.

Table 2 is modified from *Morbidity and Mortality Weekly Report (MMWR) RR-17 Guidelines for Infection Control in Dental Health Care Settings- 2003* (29*)*

Approved at Faculty Meeting January 22, 2008
Modified November 22, 2008
Approved January 20, 2009
Updated April 9, 2019
Approved April 30, 2019

References

1. Commission on Dental Accreditation of Canada. Accreditation requirements for Doctor of Dental Surgery (DDS) or Doctor of Dental Medicine (DMD) programs Effective April 1, 2001. Updated with Practice Outcomes Assessment- November 2001. Updated November 30, 2013. In.: Commission on Dental Accreditation of Canada; 2013. p. 35.
2. Commission on Dental Accreditation of Canada. Accreditation requirements for Oral and Maxillofacial Surgery programs Effective November 30, 2003. Updated November 30, 2013. In.: Commission on Dental Accreditation of Canada; 2013. p. 17.
3. Commission on Dental Accreditation of Canada. Accreditation requirements for Dental Hygiene programs. Effective July, 2001. Updated with Practice Outcomes Assessment- November, 2001. Updated November 30, 2015. In.: Commission on Dental Accreditation of Canada; 2015. p. 17.
4. Commission on Dental Accreditation of Canada. Accreditation requirements for Dental Residency programs Effective November 30, 2005. Updated November 2011. Updated November 2015. In.: Commission on Dental Accreditation of Canada; 2015. p. 12-13.
5. Health Canada. Proceedings of the Consensus Conference on Infected Health Care Worker Risk for transmission of bloodborne pathogens. CCDR 1998;24 Suppl 4.
6. Health Canada. Prevention and control of occupational infections in health care. An infection control guideline. Canada Communicable Disease Report. Can Commun Dis Rep 2002;28 Suppl 1:1-264.
7. Public Health Agency of Canada. Guideline on the Prevention of Transmission of Bloodborne Viruses from Infected Healthcare Workers in Healthcare Settings. November 2018.
8. Chang versus University of Iowa School of Dentistry. U.S. Department of Health and Human Services Office of Civil Rights Docket #07923091. 1995.
9. Chiarello LA, Cardo DM. Preventing transmission of hepatitis B virus from surgeons to patients. Infect Control Hosp Epidemiol 2002;23(6):301-302.
10. Centers for Disease Control and Prevention. Updated CDC recommendations for the management of hepatitis B virus-infected health-care providers and students. MMWR Recomm Rep 2012;61(RR-3):1-12.
11. Little JW, Miller CS, Rhodus NL. Little and Falace's Dental Management of the Medically Compromised Patient. 9th ed: Mosby Inc; 2018.
12. Centers for Disease Control and Prevention. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. June 29, 2001. Report No.: 50. https://www.cdc.gov/mmwr/PDF/rr/rr5011.pdf. 2001.
13. Centers for Disease Control and Prevention. Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection. Morbidity and Mortality Weekly Report. 2008;57(RR-8):1-20. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5708a1.htm. 2008.
14. Schillie S, Murphy TV, Sawyer M, Ly K, Hughes E, Jiles R, et al. CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management. MMWR Morb Mortal Wkly Rep 2013;62(rr10):1-19.
15. Bond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B virus after drying and storage for one week. http://www.sciencedirect.com/science/article/pii/S0140673681928774?via%3Dihub. Lancet 1981;1(8219):550-551.
16. Bell DM, Shapiro CN, Culver DH, Martone WJ, Curran JW, Hughes JM. Risk of hepatitis B and human immunodeficiency virus transmission to a patient from an infected surgeon due to percutaneous injury during an invasive procedure: estimates based on a model. Infectious Agents and Disease 1992;1(5):263-269.
17. Public Health Agency of Canada. Brief Report: Hepatitis B Infection in Canada. Epi-Update. http://www.phac-aspc.gc.ca/id-mi/pdf/hepB-eng.pdf. 2011.
18. Bell DM, Shapiro CN, Ciesielski CA, Chamberland ME. Preventing bloodborne pathogen transmission from health-care workers to patients. The CDC perspective. The Surgical clinics of North America 1995;75(6):1189-1203.
19. Laurenson IF, Jones DG, Hallam NF, Saunders CJ, Fraser DM, Carman WF. Transmission of hepatitis B virus from a vaccinated healthcare worker. The Journal of hospital infection 2007;66(4):393-394.
20. Center for Disease Control and Prevention. Recommendations for Preventing Transmission of Human Immunodeficiency Virus and Hepatitis B Virus to Patients During Exposure-Prone Invasive Procedures. MMWR Recomm Rep 1991;40(RR08)):1-9.

21. Buster EH, van der Eijk AA, Schalm SW. Doctor to Patient Transmission of Hepatitis B Virus: Implications of HBV DNA Levels and Potential New Solutions. http://www.sciencedirect.com/science/article/pii/S0166354203001955. J Antiviral Research 2003;60(2):79-85.
22. Corden S, Ballard AL, Ijaz S, Barbara JA, Gilbert N, Gilson RJ, et al. HBV DNA levels and transmission of hepatitis B by health care workers. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2003;27(1):52-58.
23. Molyneaux P, Reid TM, Collacott I, McIntyre PG, Dillon JF, Laing RB. Acute hepatitis B in two patients transmitted from an e antigen negative cardiothoracic surgeon. Communicable disease and public health / PHLS 2000;3(4):250-252.
24. Ngui SL, Watkins RP, Heptonstall J, Teo CG. Selective transmission of hepatitis B virus after percutaneous exposure. The Journal of infectious diseases 2000;181(3):838-843.
25. Spijkerman IJ, van Doorn LJ, Janssen MH, Wijkmans CJ, Bilkert-Mooiman MA, Coutinho RA, et al. Transmission of hepatitis B virus from a surgeon to his patients during high-risk and low-risk surgical procedures during 4 years. Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2002;23(6):306-312.
26. Sundkvist T, Hamilton GR, Rimmer D, Evans BG, Teo CG. Fatal outcome of transmission of hepatitis B from an e antigen negative surgeon. Communicable disease and public health / PHLS 1998;1(1):48-50.
27. The Incident Investigation Teams and Others. Transmission of Hepatitis B to Patients from Four Infected Surgeons Without Hepatitis B e Antigen. http://www.nejm.org/doi/full/10.1056/NEJM199701163360304. New Engl J Med 1997;336(3):178-184.
28. van der Eijk AA, de Man RA, Niesters HG, Schalm SW, Zaaijer HL. Hepatitis B virus (HBV) DNA levels and the management of HBV-infected health care workers. Journal of viral hepatitis 2006;13(1):2-4.
29. Kohn W, Collins A, Cleveland J, Harte J, Eklund K, Malvitz D. Guidelines for infection control in dental health-care settings-2003. MMWR Recomm Rep 2003;52(RR-17):1-66.
30. Miller C, Palenik C. Infection Control & Management of Hazardous Materials for the Dental Team. 3rd ed. St. Louis: Elsevier, Mosby; 2005.
31. London Department of Health. Hepatitis B infected health workers. HSC 2000/020 2000.
32. Ballard AL, Boxall EH. Assessing the infectivity of hepatitis B carriers. Communicable disease and public health / PHLS 1999;2(3):178-183.
33. Bolyard EA, Tablan OC, Williams WW, Pearson ML, Shapiro CN, Deitchmann SD. Guideline for infection control in healthcare personnel, 1998. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1998;19(6):407-463.
34. Herwaldt LA, Pottinger JM, Carter CD, Barr BA, Miller ED. Exposure workups. Infect Control Hosp Epidemiol 1997;18(12):850-871.
35. Canadian Dental Association. Code of Ethics, Article 2, Competency. 1991(November 15, 2006).

Approved at Faculty Meeting January 22, 2008
Modified November 22, 2008
Approved January 20, 2009
Updated April 9, 2019
Approved April 30, 2019

Appendix 1

DALHOUSIE UNIVERSITY
Inspiring Minds

/FACULTY OF DENTISTRY
IMMUNIZATION/CPR RECORD

Last Name	First Name	Middle Initial

Banner ID #	Birth Date (DD/MM/YY)	Phone

Mailing Address	Email

Degree Program or Position (Check One)

- ☐ Bachelor of Dental Hygiene (BDH)
- ☐ Undergraduate Program Dental Hygiene (DH)
- ☐ Doctor in Dental Surgery (DDS)
- ☐ Qualifying Program Dentistry (QP)
- ☐ Graduate Program Dentistry
- ☐ Other _____

This section to be completed and signed by your physician:

Required Immunization	Dates Immunization Received (DD/MM/YY)			Antibody Titre Results* or Laboratory Diagnosed History of Disease	
				Date	Results
Tetanus, diphtheria, pertussis (Td/Tdap) 1 dose within past 10 years	Dose 1				
Polio (IPV) Primary Course	Dose 1				
German Measles (Rubella) 2 doses after age 12 months	Dose 1	Dose 2			
Measles (Rubeola) 2 doses after age 12 months	Dose 1	Dose 2			
Mumps 2 doses after age 12 months	Dose 1	Dose 2			
Varicella (Chicken Pox) 2 doses	Dose 1	Dose 2			
Hepatitis B or A/B Series of 3 doses*	Dose 1	Dose 2	Dose 3		
Post-vaccination Serology Test (all applicants)* **1. Hepatitis B Surface Antibodies (anti-HBs)**					
Additional Post-vaccination Serology Tests (for applicants from countries endemic with HB – High & Intermediate)*					
1. Hepatitis B Surface Antigen (HBsAg)					
2. Hepatitis B Core Antibodies (anti-HBc)					

Approved at Faculty Meeting January 22, 2008
Modified November 22, 2008
Approved January 20, 2009
Updated April 9, 2019
Approved April 30, 2019

Baseline PPD (Tuberculosis Screening) 2-Step Mantoux	Step 1	Induration
	Step 2	Induration
Annual 1-Step Mantoux	Step 1	Induration
If there is a documented prior positive TST, previous treatment for active TB, or previous treatment for latent TB, a TST is not required. Medical evaluation and a chest X-ray within 1 year are required. Date of Chest X-ray: ___ / ___ / ___. Please attach copies of chest X-ray report. DD MM YY		

** Copies of antibody titre results must accompany this form.*

Physician Signature: _____ Date: _____

Influenza			
Year 1	Year 2	Year 3	Year 4
CPR / AED Certification (Annual renewal is recommended). *Copy of certification must accompany this form.*			
Year 1	Year 2	Year 3	Year 4

Authorization for Disclosure of Information

I understand that it is my responsibility to inform the appropriate personnel of any communicable disease, special need or medical condition which may place me at a risk or pose a risk to others during clinical placements. The information on the immunization form will be kept confidential within my clinical site. However, under the following circumstances and for the duration of the program, I authorize the release of this immunization record to: 1. The clinical site personnel where an occupational exposure occurs; 2. The treating medical site/institution (if required); 3. Another clinical placement site (if requested).

_____ _____
Signature of Student Date

Return Completed form to: Clinical Nurse, Faculty of Dentistry
Dalhousie University • 1459 Oxford Street • Halifax NS B3H 4R2 Canada. Forms may also be faxed to 902-494-1757.
For questions regarding this form, please call Ms. Sue Murphy @ 902-494-1673.

*Post-serology testing for applicants born or previously residing in high HBV endemic countries must include both HBcAb and HBsAg as well as HBsAg to fully define HBV status prior to acceptance into the program. This includes applicants from all countries except for those listed as having a Low (<1%) incidence of hepatitis B.

Approved at Faculty Meeting January 22, 2008
Modified November 22, 2008
Approved January 20, 2009
Updated April 9, 2019
Approved April 30, 2019



MAP 3-4. PREVALENCE OF CHRONIC HEPATITIS B VIRUS INFECTION AMONG ADULTS[1]

[1] Disease data source: Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30(12): 2212-2219.

List of countries by prevalence of chronic hepatitis B virus infection among adults:

High and Intermediate HBV Endemic Countries

High (≥8%): Benin, Burkina Faso, Cameroon, Cape Verde, Chad, Côte d'Ivoire, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, São Tomé and Príncipe, Senegal, Sierra Leone, Togo

Intermediate (5%-7%): Angola, Armenia, Azerbaijan, Botswana, Burundi, Cambodia, Central African Republic, China, Comoros, Congo, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Federal States of Micronesia, Fiji, Gabon, Georgia, Indonesia, Kazakhstan, Kenya, Kiribati, Kyrgyzstan, Lao People's Democratic Republic, Lesotho, Madagascar, Malawi, Malaysia, Maldives, Marshall Islands, Mauritius, Mongolia, Mozambique, Myanmar, Namibia, Papua New Guinea, People's Republic of Korea, Philippines, Rwanda, Samoa, Seychelles, Solomon Islands, Somalia, South Africa, Sri Lanka, Sudan, Swaziland, Taiwan, Tajikistan, Thailand, Tonga, Turkmenistan, Uganda, United Republic of Tanzania, Uzbekistan, Vanuatu, Zambia, Zimbabwe

Low Intermediate (2%-4%): Afghanistan, Albania, Algeria, Argentina, Aruba, Australia, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belize, Bhutan, Bolivia, Bosnia and Herzegovina, Brunei Darussalam, Bulgaria, Chile, Croatia, Cuba, Czech Republic, Dominica, Dominican Republic, Ecuador, Egypt, Estonia, Grenada, Guyana, Haiti, Hungary, India, Iraq, Islamic Republic of Iran, Jamaica, Japan, Jordan, Latvia, Lebanon, Libyan Arab Jamahiriya, Lithuania, Macedonia, Martinique, Moldova, Montenegro, Morocco, Nepal, Netherlands Antilles, New Zealand, Pakistan, Palestine, Peru, Poland, Puerto Rico, Republic of Korea, Romania, Russian Federation, Saint Lucia, Saint Vincent and the Grenadines, Singapore, Suriname, Trinidad and Tobago, Ukraine, Uruguay

Low HBV Endemic Countries

Low (<1%): Andorra, Austria, Belgium, Brazil, Canada, Colombia, Costa Rica, Cyprus, Denmark, El Salvador, Finland, France, Germany, Greece, Guatemala, Honduras, Iceland, Ireland, Israel, Italy, Mexico, Nicaragua, Panama, Paraguay, United States of America, Venezuela
No data: Serbia

Source: https://www.cdc.gov/travel-static/yellowbook/2016/map_3-04.pdf

Approved at Faculty Meeting January 22, 2008
Modified November 22, 2008
Approved January 20, 2009
Updated April 9, 2019
Approved April 30, 2019

Appendix 2

nova scotia health authority

OCCUPATIONAL HEALTH SAFETY & WELLNESS
Immunization & Infectious Diseases Screening

It is your responsibility to obtain proof that you have had the following vaccinations **prior** to your appointment with the Occupational Health Nurse and to bring this fully completed Form or documentation with you. As proof You **MUST** supply one of the following:

1. This form completed and signed by a Medical Doctor (MD) , Occupational Health Nurse (OHN), Nurse Practioner (NP), Registered Nurse (RN)
   OR
2. Documentation of all requirements listed below

Name: _____ _____ Date of Birth (YYYY/MM/DD): _____/_____/_____
Last Name First Name

Varicella, Tetanus/Diphtheria/Pertussis, Measles/Mumps/Rubella: All employees **must** provide written confirmation of either the vaccine series **or** proof of immunity via serology.

	Date Vaccine Given (YYYY/MM/DD)	**Serology Date** (YYYY/MM/DD)	**Serology Date & Result**
Varicella	1) 2)		
Td (Td – once every 10 years)			
TdaP (Tdap – once as an adult)			
MMR Measles Mumps Rubella	1) 2)		Measles: Mumps: Rubella:

Hepatitis B: All employees who have the potential to be exposed to blood/bodily fluids must provide written confirmation of the vaccine series and proof of immunity via serology.

Hepatitis B Series # 1	1) 2) 3)		HBsAb:
Hepatitis B Series # 2 (only required if not immune after initial series)	1) 2) 3)		HBsAb:

Tuberculosis**: For all employees who have patient contact:
- If history of TB disease or treatment with INH, please indicate and provide copy of most recent CXR. If previous BCG vaccine given, provide documentation and any TST results post-BCG. If employee has had a 1 or 2 step TST in the past, provide dates and results.
- **If no previous TB testing, OHSW can provide testing.**

Tuberculosis**	Date 1st step given:	Date of Read:	Result:	mm
	Date 2nd step given:	Date of Read:	Result:	mm
	BCG Date (if applicable):	CXR Result (if applicable):		

Signature of - MD, OHN, NP, RN: _____ **Date:** _____

SEE CONTACT LIST ON BACK FOR OCCUPATIONAL HEALTH & PUBLIC HEALTH INFORMATION

May 2017

Approved at Faculty Meeting January 22, 2008
Modified November 22, 2008
Approved January 20, 2009
Updated April 9, 2019
Approved April 30, 2019

Appendix 3

Agreement Form for Hepatitis B antibody, antigen, and Viral DNA Testing

As a health care provider, Hepatitis B is an occupational risk. I understand that due to my serology results, I remain susceptible to Hepatitis B.

I agree to undergo serological testing on an annual basis or on a schedule determined by the Faculty of Dentistry until graduation from the clinical program.

Student Name_____Signature_____

Asst. Dean, Clinics_____Signature_____

Clinic Nurse_____Signature_____

Date_____
Month / Day / Year

Approved at Faculty Meeting January 22, 2008
Modified November 22, 2008
Approved January 20, 2009
Updated April 9, 2019
Approved April 30, 2019

Appendix 4

Hepatitis B Vaccine Declination Statement

I understand that as a clinical faculty or clinical support staff employee at the Faculty of Dentistry, I am at risk of acquiring hepatitis B (HBV) infection due to occupational exposure to blood and or other body fluids. I have been advised that vaccination is a requirement. I have been provided with counseling and information regarding hepatitis B. The efficacy, safety issues and benefits regarding the hepatitis B vaccination have been explained to me. However, I decline the vaccine at this time. The **Agreement Form for Hepatitis B Antibody and Antigen Testing** must also be signed.

Student Name_____Signature_____

Asst. Dean, Clinics_____Signature_____

Clinic Nurse_____Signature_____

Date_____
Month / Day / Year